Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Oettel M et al.  
New Developments In Testosterone Therapy - a Congress Report

Journal für Reproduktionsmedizin und Endokrinologie - Journal of Reproductive Medicine and Endocrinology 2008; 5 (2): 70-75

Volltext (PDF)    Summary    Abbildungen   

Abb. 1: Hypogonadism

Keywords: erektile DysfunktionHypogonadismusMetabolisches SyndromTestosteronTherapieerectile dysfunctionmetabolic syndrometestosteronetherapy

This congress report summarizes the presentations on the association of metabolic syndrome, testosterone deficiency, erectile dysfunction andthe options of therapy with intramuscular testosterone undecanoate given at the Educational Symposium, "Testosterone Therapy: New Devel-opments in Sexual Medicine", held at the 9th Congress of the European Society for Sexual Medicine.Men presenting with erectile dysfunction might have evidence of the metabolic syndrome and of insulin resistance. One of the conse-quences of obesity and type 2 diabetes is the promotion of a hypogonadal state also featuring hepatic, skeletal muscle insulin resistance, andvisceral fat deposition. Intramuscular testosterone undecanoate fulfils the criteria for a favorable parenteral system: improved Pharmacokineticsallowing injections four times a year without clinically significant non-physiological peaks or troughs of serum testosterone levels in hypogonadalmen.Identification and treatment of hypogonadism and metabolic syndrome are certainly beneficial for the overall health of the male patient,and may also benefit erectile dysfunction.
copyright © 2000–2024 Krause & Pachernegg GmbH | Sitemap | Datenschutz | Impressum